Neuroendocrine tumours or carcinomas

Experience:

• A phase II single arm trial evaluating the preliminary efficacy of the combination of XXX and XXX in Grade 3 well-differentiated neuroendocrine tumours (NET) or poorly differentiated neuroendocrine carcinomas (NEC)